Google
IPSC — CENTURY THERAPEUTICS INC (Healthcare >> Biotechnology)
IPSC FAQ
What is IPSC's ROE?
CENTURY THERAPEUTICS INC reports a Return on Equity (ROE) of -40.71%.
What is IPSC's dividend yield?
CENTURY THERAPEUTICS INC offers a dividend yield of 0.00%.
What is IPSC's Deepscope Quality Score?
Deepscope rates IPSC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IPSC?
Deepscope's AI Timing Score for IPSC is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IPSC belong to?
CENTURY THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.13
Price
-0.07
(-3.18%)
Day Change
|
|
|---|
IPSC, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.13 |
| PBV / Sector |
1.50 / 4.63
GOOD
|
| Earning Per Share | -0.58 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.09 M
GREAT
|
| Average 1W Daily Value |
2.66 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:47 |
| Symbol | IPSC |
| Name | CENTURY THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 180.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 396.78 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 25 North 38th Street, Philadelphia, PA, United States, 19104
Phone: 267 817 5790
Website: https://www.centurytx.com
Employees: 78
Sector: Healthcare >> Biotechnology
Description: Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
